SCHEDULE 13G: BlackRock Discloses 5.8% Stake in Cardiff Oncology, Inc.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Cardiff Oncology, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,841,097 shares of Cardiff Oncology, Inc. common stock.
• This ownership represents 5.8% of the total outstanding common stock of Cardiff Oncology, Inc.
• BlackRock, Inc. holds sole voting power over 3,801,271 shares and sole dispositive power over 3,841,097 shares.
• The filing was made under Rule 13d-1(b), indicating BlackRock, Inc. is a parent holding company (HC).
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Cardiff Oncology, Inc.

Sentiment

Score: 7

Explanation: While a routine disclosure, the filing of a significant stake by a major institutional investor like BlackRock can be viewed positively by the market as a vote of confidence in the company, even if it's not an active investment decision to influence the company's operations.

Positives

• BlackRock, Inc., a prominent institutional investor, has disclosed a significant 5.8% beneficial ownership stake in Cardiff Oncology, Inc., which may be interpreted by the market as a vote of confidence in the company.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive landscape for Cardiff Oncology, Inc.

Stakeholder Impact

• Shareholders: May view BlackRock's significant stake as a positive signal, potentially increasing investor confidence.
• Company Management: Awareness of a major institutional holder, though BlackRock states no intent to influence control.

Key Dates

Recommendation

Keywords

Cardiff Oncology, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing